7/9/2019 8:10:28 AM
CytomX Says Target Selection Triggers $10 Mln Payment From AbbVie
2/5/2019 8:08:28 AM
CytomX Therapeutics Appoints Nick Galli SVP, Chief Business Officer And Leslie Robbins SVP, Intellectual Property
1/7/2019 8:24:45 AM
CytomX Acquires Drug Conjugate Linker-toxin And CD3-based Bispecific Technologies From Agensys
12/20/2018 8:11:00 AM
CytomX Therapeutics: President And CEO Sean McCarthy Appointed To Additional Role Of Chairman
11/7/2018 9:22:48 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY18 Rev. Estimate To 66.5 M From 72.5 M
11/7/2018 9:21:37 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY18 Estimate To -1.68 From -1.53
11/6/2018 8:16:58 AM
CytomX To Present Clinical Translational Data From PROCLAIM-CX-072, An Ongoing Phase 1/2 Trial Evaluating CX-072
10/22/2018 6:50:20 AM
CytomX Therapeutics Presents Clinical Data From Probody Platform And CX-072 At 2018 ESMO Annual Meeting
7/17/2018 4:07:50 PM
CytomX Therapeutics Announces Closing Of Public Offering Of Common Stock
7/10/2018 4:04:03 PM
CytomX Therapeutics Announces Proposed Public Offering Of Common Stock
6/4/2018 9:13:38 AM
CytomX Presents Preliminary Clinical Proof-of-Concept Data From Probody Platform And CX-072
5/22/2018 7:34:21 AM
CytomX Therapeutics Announces FDA Clearance Of Investigational New Drug Application For CX-2029
5/10/2018 7:26:02 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) FY18 Rev. Estimate To 69.7 M From 74.0 M
5/10/2018 7:25:36 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY18 Estimate To -1.45 From -1.28
5/10/2018 7:25:11 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) Q4 18 Estimate To -0.38 From -0.36
5/10/2018 7:24:59 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) Q3 18 Estimate To -0.35 From -0.34
5/10/2018 7:24:49 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) Q2 18 Estimate To -0.32 From -0.31